Anabolikler & SARM

ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia. In healthy volunteers, a single dose produced significant increases in lean mass and reductions in fat mass within 29 days.

Anadrol (oxymetholone) is one of the most potent oral anabolic steroids ever developed, originally synthesized in the 1960s by Syntex Pharmaceuticals. It was FDA-approved for the treatment of anemias caused by deficient red blood cell production, including aplastic anemia, myelofibrosis, and anemia associated with chronic kidney disease. Anadrol is a DHT-derived compound with a 17-alpha alkylated structure that allows oral bioavailability at the cost of significant hepatic strain. In performance enhancement contexts, it is regarded as the single most powerful oral steroid for rapid mass and strength gains, capable of producing dramatic weight increases of 10-15+ pounds in the first few weeks of use. Despite being a DHT derivative that does not aromatize via the aromatase enzyme, Anadrol produces notable estrogenic side effects including water retention and gynecomastia through a poorly understood mechanism believed to involve direct activation of estrogen receptors. This makes estrogen management uniquely challenging compared to other anabolic steroids.

Anastrozole is a potent, selective, nonsteroidal aromatase inhibitor that blocks the enzyme aromatase (CYP19A1), preventing the conversion of androgens (testosterone and androstenedione) into estrogens (estradiol and estrone). It is FDA-approved under the brand name Arimidex for the treatment of hormone receptor-positive breast cancer in postmenopausal women. In the bodybuilding and hormone optimization community, anastrozole is widely used as an ancillary compound during testosterone or anabolic steroid cycles to manage estrogen-related side effects such as gynecomastia, water retention, and elevated blood pressure. Unlike SERMs, which block estrogen at the receptor, anastrozole reduces circulating estrogen levels directly by inhibiting its synthesis. This distinction is clinically important: while effective at preventing estrogenic side effects, anastrozole carries the risk of suppressing estrogen too aggressively, which can impair joint health, bone density, cardiovascular markers, and mood. A common starting-point rule of thumb: weekly testosterone dose (mg) divided by 500 equals mg of anastrozole per week. For example, 500 mg of testosterone per week would correspond to roughly 1 mg of anastrozole per week, split across injection days. This is only a rough guideline -- individual aromatization rates vary widely, and dosing should always be refined based on bloodwork.

Boldenone is a synthetic anabolic-androgenic steroid derived from testosterone by the introduction of a 1,2-double bond (dehydrogenation at the C1-C2 position). It was originally developed in the 1960s as a long-acting injectable veterinary steroid under the trade name Equipoise for use in horses. Boldenone has never been approved by the FDA for human medical use, and no pharmaceutical-grade human formulation has been marketed. Despite its veterinary origins, boldenone has become one of the more widely used anabolic steroids in bodybuilding and strength sports, valued for producing lean, quality muscle gains with less water retention than testosterone, enhanced vascularity, increased appetite, and a notable boost in red blood cell production and endurance capacity. Its anabolic rating is approximately 100 (equal to testosterone), while its androgenic rating is roughly 50 (half that of testosterone), giving it a favorable anabolic-to-androgenic ratio. Boldenone aromatizes to estradiol at approximately 50% the rate of testosterone, and the compound itself has been reported to possess mild aromatase inhibitor-like properties through its metabolite 1,4-dienedione. The undecylenate ester produces a very long-acting compound with a half-life of approximately 14 days, meaning effects build slowly and the compound has a prolonged detection window of roughly 5 months in anti-doping tests.

Dihydroboldenone (DHB), also known as 1-testosterone, is the 5-alpha reduced metabolite of boldenone. While boldenone itself is converted to DHB in the body via 5-alpha reductase, standalone DHB is used as an injectable anabolic steroid in its own right, most commonly as the cypionate ester. DHB occupies an unusual niche in the anabolic steroid landscape: it possesses a high anabolic rating (approximately 200, double that of testosterone) with a moderate androgenic rating (approximately 100, equal to testosterone), producing lean, dry gains with no estrogenic activity. These properties have led to frequent comparisons with Primobolan (methenolone), as both compounds promote quality lean tissue gains without water retention or estrogen-related side effects. However, DHB is generally considered more potent milligram-for-milligram than Primobolan and is significantly cheaper, making it an attractive alternative for users seeking similar aesthetic results at lower cost. The compound has never been approved by the FDA for any medical indication, and all available DHB products are manufactured by underground laboratories. DHB's most notable drawback is severe post-injection pain (PIP), which is widely reported even at moderate concentrations and can be debilitating enough to limit practical use. This PIP is attributed to the compound's high melting point and crystalline nature, which causes it to precipitate out of solution in muscle tissue after injection, triggering a localized inflammatory response.

Dianabol (methandrostenolone) is the original oral anabolic steroid, developed in the late 1950s by Dr. John Ziegler in collaboration with Ciba Pharmaceuticals for the US Olympic team. It was briefly FDA-approved for medical use but was discontinued from the US market in the 1980s due to abuse potential and side effect concerns. Despite its removal from pharmaceutical production, Dianabol remains one of the most widely used performance-enhancing compounds in the world due to its rapid and dramatic effects on muscle mass and strength. It is a 17-alpha-alkylated derivative of testosterone with an added C1-C2 double bond, which shifts its profile toward more anabolic and less androgenic activity compared to testosterone. Dianabol aromatizes heavily to methylestradiol, causing significant water retention and estrogenic side effects. Its short half-life of 4-6 hours necessitates split dosing throughout the day for stable blood levels. It is most commonly used as a 4-6 week kickstart to injectable cycles, providing rapid size and strength gains while longer-acting compounds like testosterone enanthate or cypionate reach steady-state levels.

Ecdysterone (20-Hydroxyecdysone) is a naturally occurring phytoecdysteroid -- a class of steroid hormones that regulate molting and metamorphosis in insects and crustaceans. Despite its name and steroidal structure, ecdysterone does not interact with the androgen receptor and operates through an entirely different mechanism than anabolic-androgenic steroids. It is found in meaningful concentrations in common foods such as spinach (Spinacia oleracea), quinoa (Chenopodium quinoa), and various other plants. Ecdysterone gained significant attention in the strength and performance community following a 2019 study from Freie Universitat Berlin, which demonstrated that trained individuals supplementing with ecdysterone experienced significantly greater muscle mass gains compared to placebo over a 10-week resistance training program. The effect sizes were large enough that the study authors themselves recommended the World Anti-Doping Agency (WADA) consider adding ecdysterone to the prohibited substances list. Unlike traditional anabolic agents, ecdysterone does not cause hormonal suppression, does not require post-cycle therapy, and carries an exceptionally mild side effect profile. Its mechanism appears to involve signaling through estrogen receptor beta (ERbeta), which activates anabolic pathways in skeletal muscle without the androgenic, estrogenic, or hepatotoxic effects associated with traditional performance-enhancing compounds. An injectable form has gained popularity among advanced users seeking higher bioavailability, as oral ecdysterone suffers from significant first-pass metabolism.

Exemestane is a steroidal, irreversible aromatase inhibitor (often called a suicide inhibitor) that permanently inactivates the aromatase enzyme (CYP19A1), preventing conversion of androgens into estrogens. It is FDA-approved under the brand name Aromasin for the treatment of hormone receptor-positive breast cancer in postmenopausal women, particularly after prior tamoxifen therapy. In bodybuilding and hormone optimization, exemestane is valued for two properties that distinguish it from nonsteroidal AIs like anastrozole: its irreversible binding mechanism means there is no estrogen rebound when the drug is discontinued, and its steroidal structure confers mild androgenic activity that may partially offset some of the joint and mood side effects associated with estrogen suppression. Because exemestane permanently destroys aromatase molecules rather than temporarily blocking them, estrogen levels recover only as the body synthesizes new enzyme -- a process that takes several days. A common rule of thumb from community dosing guidelines: weekly testosterone dose (mg) divided by 20 equals mg of exemestane per week. For example, 500 mg of testosterone per week corresponds to approximately 25 mg of exemestane per week. This is a rough starting point only -- individual aromatization rates vary widely, and dosing should always be guided by bloodwork.

Halotestin (fluoxymesterone) is a synthetic oral anabolic-androgenic steroid derived from testosterone, first introduced in the late 1950s by Upjohn under the brand name Halotestin. It is characterized by an extraordinarily high androgenic rating of approximately 1900 relative to testosterone, paired with an anabolic rating of roughly 1900 as well, though its real-world muscle-building effects are far less pronounced than these numbers suggest. The compound was originally FDA-approved for the treatment of male hypogonadism and advanced breast cancer in women, though it is rarely prescribed today due to the availability of safer alternatives. Fluoxymesterone does not aromatize to estrogen, meaning it produces no estrogenic side effects such as water retention or gynecomastia. In performance contexts, halotestin is used almost exclusively by advanced athletes and competitive bodybuilders in the final weeks before competition or powerlifting meets, where its ability to dramatically increase aggression, neural drive, and strength output without adding water weight makes it uniquely valuable. It is considered one of the harshest oral steroids with respect to hepatotoxicity and is unsuitable for general physique enhancement or beginner use.

Letrozole is the most potent of the three commonly used aromatase inhibitors (letrozole > anastrozole > exemestane), capable of suppressing circulating estradiol by approximately 98% at the standard medical dose of 2.5mg daily. It is FDA-approved under the brand name Femara for the treatment of hormone receptor-positive breast cancer in postmenopausal women and is also used off-label for ovulation induction in fertility medicine. In the bodybuilding and hormone optimization context, letrozole is often considered the "nuclear option" among AIs -- reserved for severe gynecomastia flare-ups, very high aromatizing cycles, or situations where anastrozole has proven insufficient. Its extreme potency is a double-edged sword: while it is highly effective at controlling estrogen, it is also very easy to crash estrogen to undetectable levels, which produces debilitating side effects including severe joint pain, profound fatigue, mood disturbance, and impaired sexual function. Most experienced users treat letrozole as a rescue compound rather than a first-line estrogen management tool, reaching for it only when other options have failed or when rapid, aggressive estrogen suppression is genuinely necessary.

LGD-4033 (Ligandrol) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics (under the designation VK5211). It is one of the most widely studied SARMs in clinical trials, having completed Phase 1 safety studies in healthy volunteers and a Phase 2 trial evaluating its efficacy in patients recovering from hip fracture surgery. LGD-4033 was designed to provide anabolic benefits, specifically increased lean muscle mass and improved physical function, with reduced androgenic side effects compared to testosterone. In clinical studies, it demonstrated dose-dependent increases in lean body mass, leg press strength, and stair-climbing speed in hip fracture patients. LGD-4033 is broadly considered the most potent SARM for lean mass accrual, exceeding Ostarine (MK-2866) in anabolic potency at comparable doses. Despite promising clinical data, LGD-4033 is not approved by any regulatory agency for any medical indication. Its widespread use in performance enhancement contexts is based on a combination of clinical trial data, preclinical studies, and anecdotal reports.

Masteron (drostanolone) is a synthetic dihydrotestosterone (DHT)-derived anabolic-androgenic steroid originally developed and marketed as Masteril and Drostanolone Propionate for the treatment of inoperable breast cancer in postmenopausal women. It received FDA approval for this indication in the 1970s but has since been discontinued from pharmaceutical markets. Structurally, drostanolone is DHT with a 2-alpha-methyl group, which increases its anabolic potency and protects it from metabolic breakdown by 3-alpha-hydroxysteroid dehydrogenase in muscle tissue. As a DHT derivative, Masteron does not aromatize to estrogen and exhibits mild anti-estrogenic properties, likely through competitive inhibition at the aromatase enzyme or direct antagonism at the estrogen receptor. This makes it uniquely suited for cutting and contest preparation cycles where a dry, hard, and grainy physique is desired. Masteron is not a mass-building compound; its primary value lies in aesthetic enhancement, estrogen management, and synergy with other anabolic agents. It is available in two ester forms: the short-acting propionate (original pharmaceutical form) and the longer-acting enanthate (underground lab formulation). Effective results are most visible at lower body fat percentages, typically below 12-15%, where its hardening and drying effects become pronounced.

MENT (7-alpha-methyl-19-nortestosterone), also known as trestolone, is an experimental synthetic anabolic-androgenic steroid that belongs to the 19-nor (nandrolone) family. It was originally developed by the Population Council as a potential male hormonal contraceptive and androgen replacement therapy. MENT is estimated to be roughly 10 times more potent than testosterone on a milligram-per-milligram basis, which allows for effective use at very low doses. Unlike nandrolone, MENT does not cause the characteristic sexual dysfunction ('deca dick') associated with other 19-nor compounds, because it maintains sufficient androgenic activity in the central nervous system and sexual tissues. This property has generated significant interest in MENT as a potential standalone replacement for testosterone -- a compound that could serve as both the anabolic and androgenic base in hormone replacement protocols. MENT aromatizes, but its aromatization product is 7-alpha-methyl-estradiol rather than standard estradiol. This methylated estrogen behaves differently from estradiol in some respects, and aromatase inhibitors like anastrozole have reduced efficacy against it. Estrogen management on MENT is therefore considered more challenging than with testosterone. The acetate ester is the most widely available formulation and has an extremely short half-life of approximately 40 minutes, necessitating daily or twice-daily injections for stable blood levels. Research into longer-acting esters and delivery systems (including subdermal implants) is ongoing. MENT remains an investigational compound with no current FDA approval, though Phase 2 clinical trials for male contraception have been conducted.

MK-2866 (Ostarine, Enobosarm) is a non-steroidal selective androgen receptor modulator (SARM) originally developed by GTx, Inc. (now Oncternal Therapeutics) for the prevention and treatment of muscle wasting and sarcopenia. It is the most extensively studied SARM in clinical trials, having progressed through Phase I, II, and III trials for cancer-related cachexia, stress urinary incontinence, and age-related muscle loss. MK-2866 selectively binds to androgen receptors in muscle and bone tissue with high affinity while exhibiting minimal activity in prostate and sebaceous glands, which differentiates it from traditional anabolic-androgenic steroids. Despite promising clinical data demonstrating significant lean body mass gains in cancer patients and elderly subjects, the FDA has not granted approval, and GTx's New Drug Application for stress urinary incontinence was not approved in 2018. MK-2866 remains classified as an investigational compound and is prohibited by WADA in competitive sports.

Nandrolone is a synthetic 19-nortestosterone anabolic-androgenic steroid that has been in clinical use since the 1960s. Structurally, it differs from testosterone by the absence of a methyl group at the C19 position, which significantly reduces its androgenic activity relative to its anabolic potency. Nandrolone decanoate (Deca-Durabolin) was FDA-approved for the treatment of anemia associated with chronic renal failure and has also been used clinically for osteoporosis, wasting diseases, and severe burn recovery. Among anabolic steroids, nandrolone is particularly valued for its positive effects on collagen synthesis, joint health, and bone mineral density. It has one of the most favorable anabolic-to-androgenic ratios of any synthetic steroid (approximately 125:37 compared to testosterone at 100:100), making it a frequent choice for individuals seeking muscle growth with reduced androgenic side effects. Nandrolone is available in two primary ester formulations: the long-acting decanoate ester and the shorter-acting phenylpropionate ester (NPP).

Oxandrolone is a synthetic oral anabolic-androgenic steroid derived from dihydrotestosterone (DHT), first synthesized in 1962 by Raphael Pappo at Searle Laboratories and introduced to the market in 1964 under the brand name Anavar. It was designed to be a mild anabolic agent with minimal androgenic activity, achieved through a structural modification where an oxygen atom replaces the carbon-2 atom in the A-ring of the DHT backbone. This modification significantly reduces androgenic potency while preserving anabolic effects on skeletal muscle. Oxandrolone is FDA-approved for the promotion of weight regain following involuntary weight loss due to surgery, chronic infection, severe trauma, and prolonged corticosteroid use, and for the relief of bone pain associated with osteoporosis. It has been extensively studied in burn recovery, HIV/AIDS-related wasting, and pediatric growth disorders. Among oral anabolic steroids, oxandrolone is considered one of the mildest with respect to hepatotoxicity and virilizing side effects, which has made it one of the few anabolic steroids used in women and children in clinical settings.

Primobolan (metenolone) is a dihydrotestosterone (DHT)-derived anabolic steroid that has been in clinical and performance use since the 1960s. It was originally marketed by Schering as Primobolan (oral acetate) and Primobolan Depot (injectable enanthate) for the treatment of muscle wasting diseases, malnutrition, and osteoporosis. Although it was once FDA-approved in the United States, it has since been discontinued from the US market and is primarily available through international pharmacies and underground production. Primobolan is widely considered one of the mildest and safest anabolic steroids in terms of side effect profile. It does not aromatize to estrogen, carries low androgenic activity relative to its anabolic effects (anabolic-to-androgenic ratio of approximately 88:44 compared to testosterone at 100:100), and the injectable form is not hepatotoxic. It gained legendary status in golden-era bodybuilding, with Arnold Schwarzenegger reportedly favoring it as part of his competition preparation. Primobolan is particularly valued for lean tissue preservation during caloric deficits, quality muscle gains without water retention, and its compatibility with longer cycle durations due to its mild nature. Its primary drawback is cost -- it is one of the most expensive anabolic steroids per milligram, and effective doses require relatively high volumes of oil for injection.

Proviron (mesterolone) is an orally active dihydrotestosterone (DHT) derivative that has been used in clinical medicine since the 1960s, primarily in Europe and other international markets. Unlike most oral anabolic steroids, Proviron is not 17-alpha alkylated, which gives it a remarkably low hepatotoxicity profile. It was originally developed for the treatment of androgen deficiency, male infertility (at low doses it can improve sperm quality without fully suppressing the HPT axis), and mood disturbances related to low androgen status. Proviron is approved in numerous countries outside the United States including Germany, the UK, and several countries across Asia, South America, and the Middle East. Its most distinctive pharmacological property is its exceptionally strong binding affinity for sex hormone-binding globulin (SHBG), which effectively displaces testosterone from SHBG and increases the proportion of circulating free testosterone. This mechanism makes Proviron a popular adjunct to testosterone replacement therapy and performance enhancement protocols, where it amplifies the biological activity of co-administered testosterone without meaningfully increasing total androgen load. Proviron is also valued for its anti-estrogenic properties — as a DHT derivative, it cannot aromatize to estrogen, and it competes with testosterone for the aromatase enzyme, reducing overall estrogen conversion. Users consistently report improvements in mood, libido, confidence, and a general sense of well-being, along with a harder, drier, and more defined physical appearance.

RAD-140 (Testolone) is a nonsteroidal investigational selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. for the potential treatment of muscle wasting conditions and hormone receptor-positive breast cancer. It was designed to provide the anabolic benefits of testosterone, specifically increased lean muscle mass and bone density, while minimizing androgenic side effects in tissues such as the prostate and skin. RAD-140 has demonstrated a high degree of tissue selectivity in preclinical models, with an anabolic-to-androgenic ratio substantially greater than that of testosterone. It entered Phase 1 clinical trials for metastatic breast cancer (ER+/HER2-) and has shown preliminary safety and tolerability in that context. However, RAD-140 is not approved for any medical use by any regulatory agency. It remains a research compound, and its widespread use in performance and physique enhancement contexts is based almost entirely on preclinical data and anecdotal reports rather than completed clinical trials for those indications.

Superdrol (methyldrostanolone, also known as methasterone) is a synthetic oral anabolic-androgenic steroid derived from drostanolone (Masteron) with the addition of a 17-alpha-methyl group for oral bioavailability. It is widely regarded as one of the most potent oral anabolic steroids ever produced, delivering dramatic strength and lean mass gains in very short timeframes. Superdrol was originally marketed in the United States as a "prohormone" dietary supplement beginning in 2005 by Designer Supplements, exploiting a regulatory loophole since it was not explicitly listed as a controlled substance at the time. It was pulled from the market and subsequently classified as a Schedule III controlled substance under the Designer Anabolic Steroid Control Act of 2014. Despite its remarkable anabolic potency, Superdrol carries an extreme hepatotoxicity profile that distinguishes it from virtually all other commonly used oral steroids. Cases of severe cholestatic jaundice, liver failure, and hospitalizations have been reported even at moderate doses and short cycle lengths. It does not aromatize to estrogen, which means it does not cause water retention or gynecomastia, but this also means it provides no estrogenic support for joints, mood, or libido when used without a testosterone base. Superdrol is strictly an advanced-only compound and is not suitable for beginners under any circumstances.

Testosterone is the primary endogenous androgenic-anabolic steroid hormone produced mainly by the Leydig cells of the testes in males and in smaller quantities by the ovaries and adrenal glands in females. It is essential for the development and maintenance of male reproductive tissues, secondary sexual characteristics, muscle mass, bone density, red blood cell production, and overall well-being. Exogenous testosterone has been FDA-approved for the treatment of male hypogonadism since the 1950s and remains the gold standard for testosterone replacement therapy (TRT). It is available in multiple pharmaceutical formulations including intramuscular injectables, transdermal gels, transdermal patches, subcutaneous pellets, and oral capsules. In supraphysiological doses, testosterone is also widely used for performance enhancement, though such use falls outside approved medical indications.

Trenbolone is a synthetic 19-nortestosterone derivative and one of the most potent anabolic-androgenic steroids in common use. Originally developed for veterinary applications -- specifically as the implant pellet product Finaplix for increasing feed efficiency and lean mass in cattle -- trenbolone has never been approved for human medical use. The sole exception was a brief period in the 1980s and 1990s when trenbolone hexahydrobenzylcarbonate was marketed as Parabolan in France for human clinical use, primarily for muscle wasting and cachexia, before being voluntarily discontinued. Trenbolone's pharmacological profile is remarkable: it exhibits approximately five times the anabolic and androgenic potency of testosterone, reflected in its anabolic:androgenic ratio of 500:500 compared to testosterone's 100:100. This extraordinary potency stems from three conjugated double bonds in its steroid nucleus that dramatically enhance androgen receptor binding affinity. Unlike its parent compound nandrolone, trenbolone does not aromatize to estrogen, which contributes to its pronounced ability to produce lean, dry gains without significant water retention. However, trenbolone does exhibit significant progestogenic activity, which can elevate prolactin levels and produce a distinct set of side effects unrelated to estrogen. Trenbolone is widely regarded as the most powerful commonly available anabolic steroid for body recomposition -- simultaneously building muscle while reducing body fat. This reputation comes at a considerable cost: trenbolone carries one of the harshest side effect profiles of any steroid, including insomnia, night sweats, cardiovascular strain, respiratory distress upon injection (tren cough), anxiety, and aggression. It is strictly an advanced-only compound that should never be used by beginners or individuals without extensive experience managing anabolic steroid cycles and their ancillary requirements.

Turinabol (4-chlorodehydromethyltestosterone) is a synthetic oral anabolic-androgenic steroid developed in the 1960s by Jenapharm, an East German pharmaceutical company. It was created by modifying the structure of methandrostenolone (Dianabol) with a 4-chloro substitution derived from clostebol, producing a compound with a significantly altered pharmacological profile. Turinabol became notorious as the cornerstone of East Germany's state-sponsored doping program (Staatsplan 14.25), which systematically administered the drug to thousands of Olympic athletes from the late 1960s through the 1980s, often without their knowledge. The 4-chloro modification prevents aromatization to estrogen, meaning turinabol does not cause water retention, gynecomastia, or other estrogen-related side effects. This made it particularly attractive for athletes in weight-class sports and those requiring speed, strength, and endurance without visible changes in body mass. Unlike many oral anabolic steroids, turinabol produces slow, steady, lean gains rather than rapid increases in size and strength. It has never been approved for medical use by the FDA or any current Western regulatory body, and it was withdrawn from the market following German reunification and the exposure of the East German doping program. Today it remains one of the most commonly detected substances in anti-doping testing due to the discovery of long-term metabolites detectable for many months after last use.

Winstrol is the brand name for stanozolol, a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). It was developed in 1962 by Winthrop Laboratories and approved by the FDA for the treatment of hereditary angioedema, a condition characterized by episodic swelling of the face, extremities, genitals, bowel wall, and upper airway. Stanozolol is structurally unique among DHT derivatives due to the addition of a pyrazole group fused to the A-ring, which significantly alters its pharmacological profile. It possesses a high anabolic-to-androgenic ratio (320:30 relative to methyltestosterone), making it one of the more anabolic oral steroids available. Winstrol does not aromatize to estrogen, producing no estrogenic side effects such as water retention or gynecomastia, which has made it a staple compound in cutting and pre-contest bodybuilding protocols. It is available in both oral tablet and injectable aqueous suspension forms, with both preparations being 17-alpha-alkylated and therefore hepatotoxic. Winstrol gained widespread notoriety after sprinter Ben Johnson tested positive for it following his gold medal performance at the 1988 Seoul Olympics, which remains one of the most publicized doping cases in sports history.

YK-11 is a steroidal compound that occupies a unique position among selective androgen receptor modulators (SARMs) due to its dual mechanism of action: it functions as both a partial agonist of the androgen receptor and an inhibitor of myostatin through upregulation of follistatin. First described by Kanno et al. in 2011, YK-11 was identified in cell-based assays as a compound that selectively activates androgen-responsive gene transcription while simultaneously inducing follistatin expression, a glycoprotein that binds and neutralizes myostatin, a negative regulator of muscle growth. Unlike all other commercially known SARMs, YK-11 possesses a steroidal backbone structurally related to dihydrotestosterone (DHT), making its classification as a traditional SARM debatable. It is more accurately described as a steroidal SARM hybrid with myostatin-inhibiting properties. The research base for YK-11 is extremely limited. All published data comes from in vitro (cell culture) studies only. There are no animal studies, no pharmacokinetic studies, and no human clinical trials. As a result, virtually everything reported about YK-11's effects in living organisms, its half-life, optimal dosing, and side effect profile, is derived from structural analogy to related compounds, theoretical pharmacology, and anecdotal user reports. YK-11 is not approved for any medical use and is classified as an investigational research chemical.